Latest News and Press Releases

Key finding is that SENS-401 was effective even when time between acoustic trauma and treatment initiation reached up to four days MONTPELLIER, France, April 23, 2018 (GLOBE NEWSWIRE) -- Sensorion...

New study shows prestin in the blood following noise-induced trauma may be a biomarker for hearing loss MONTPELLIER, France, April 23, 2018 (GLOBE NEWSWIRE) -- New preclinical study findings...

Increase in operating costs consistent with advancing clinical development of SENS-111 for acute unilateral vestibulopathy (severe vertigo) and SENS-401 for sudden sensorineural hearing...

MONTPELLIER, France, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468:ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces new data presented in...

MONTPELLIER, France, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that it will present...

MONTPELLIER, France, Dec. 21, 2017 (GLOBE NEWSWIRE) -- (FR0012596468 — ALSEN) — Sensorion, a biotech specializing in the treatment of inner ear diseases (the "Company"), announces that it has today...

MONTPELLIER, France, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN / PEA-PME eligible), a biotech company pioneering novel treatments of inner ear diseases, today announced that...

Sensorion and Cochlear will evaluate SENS-401 in combination with Cochlear’s cochlear implants in preclinical setting in 2018, with potential mid-stage clinical testing to begin as soon as...

Advancing clinical development for SENS-111 and SENS-401 drug candidatesCash position of €9.2 million as of June 30, 2017 MONTPELLIER, France, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Sensorion...